Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...7891011121314151617...3233»
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  COVID-19-Impfungen: Replizierend oder Nichtreplizierend? – Der Vektor in Sputnik-V. (Pubmed Central) -  Aug 6, 2021   
    The Gamaleya institute developed the COVID-19 vaccine named Sputnik (Gam-COVID-Vac) using adenoviral vectors ad 26 and ad5 to incorporate a full SARS-Spike Protein for vaccination...Final approval by governing health authorities (e. g. EMA) should therefore be awaited.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Enrollment closed:  Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan (clinicaltrials.gov) -  Aug 5, 2021   
    P=N/A,  N=82, Active, not recruiting, 
    EMA) should therefore be awaited. Recruiting --> Active, not recruiting
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    [VIRTUAL] Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: a case report (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_966;    
    Our patient met the ADEM diagnostic criteria set by the International Pediatric MS Study Group and alternative diagnoses were excluded. Although a plausible relationship was not demonstrated, the possibility of an association with vaccine is suspected.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    [VIRTUAL] Safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America (ePoster Library) -  Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_765;    
    COVID-19 vaccines seem to be safe for pwMS from Latin America. No major safety signals appeared in this patient-reported study.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose. (Pubmed Central) -  Jul 27, 2021   
    The high seroconversion rate after a single dose in naïve participants suggests a benefit of delaying second dose administration to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.